BREAKING
Encompass Health Corporation reports Q4 2025 results, issues 2026 guidance 7 hours ago Graham Corporation Expands Capabilities Across Defense, Energy, and Space Markets 7 hours ago Graham Corporation Sees Robust Q3 on Defense Momentum and FlackTek Integration 7 hours ago Biogen’s Q4 FY25 adj. earnings decline, but beat estimates; revenue down 7% 8 hours ago Infographic: How Philip Morris (PM) performed in Q4 2025 financial results 9 hours ago Abbott reports positive results from study on its atrial fibrillation therapies 9 hours ago Atmus Welcomes Heath Sharp to Board of Directors 11 hours ago Cboe Global Markets Q4 2025 adj. earnings jump on record high revenues 11 hours ago Zurn Elkay beats fourth quarter estimates, forecasts growth for 2026 2 days ago Yum China Reports Fourth Quarter and Full Year 2025 Financial Results 2 days ago Encompass Health Corporation reports Q4 2025 results, issues 2026 guidance 7 hours ago Graham Corporation Expands Capabilities Across Defense, Energy, and Space Markets 7 hours ago Graham Corporation Sees Robust Q3 on Defense Momentum and FlackTek Integration 7 hours ago Biogen’s Q4 FY25 adj. earnings decline, but beat estimates; revenue down 7% 8 hours ago Infographic: How Philip Morris (PM) performed in Q4 2025 financial results 9 hours ago Abbott reports positive results from study on its atrial fibrillation therapies 9 hours ago Atmus Welcomes Heath Sharp to Board of Directors 11 hours ago Cboe Global Markets Q4 2025 adj. earnings jump on record high revenues 11 hours ago Zurn Elkay beats fourth quarter estimates, forecasts growth for 2026 2 days ago Yum China Reports Fourth Quarter and Full Year 2025 Financial Results 2 days ago
ADVERTISEMENT
Market News

Tilray’s (TLRY) loss widens in Q3; revenue beats estimates

Tilray’s (NASDAQ: TLRY) loss of $0.36 per share in the third quarter was wider than the year-ago loss of $0.20 per share. Analysts expected the company to post a loss of $0.30 per share. The cannabis company grew its revenue by 409% to $51.1 million in the third quarter of 2019 versus the market’s expectation […]

$TLRY November 12, 2019 2 min read

Tilray’s (NASDAQ: TLRY) loss of $0.36 per share in the third quarter was wider than the year-ago loss of $0.20 per share. Analysts expected the company to post a loss of $0.30 per share. The cannabis company grew its revenue by 409% to $51.1 million in the third quarter of 2019 versus the market’s expectation of $49.5 million. TLRY stock rose about 2% immediately after the earnings announcement in the after-market session.

Tilray (TLRY) Q3 2019 earnings - financial summary

Tilray’s revenue growth was driven by the Canadian adult-use market, the Manitoba Harvest acquisition, and growth in international medical markets as a result of the first GMP certification of the Portugal facility.

Tilray sold 10,848 kilograms of weed in the recently ended quarter compared to 1,613 kilograms sold in the prior-year quarter. The average net selling price per gram decreased to $3.25 from $6.21 in the year-ago quarter, due to the shift in product and channel mix.

“We are in the early days of seeing our strategic initiatives bear fruit – including our European expansion, brand portfolio evolution and strategic partnership product launches. We continue to expect significant growth in the fourth quarter and into 2020,” said CEO Brendan Kennedy.

The Nanaimo, British Columbia-based weed firm entered into an agreement to acquire cannabis retailer FOUR20 at the end of August. This transaction is expected to complete by the end of the first quarter of 2020.

ADVERTISEMENT

Under the agreement terms, Tilray will deliver up to C$110 million consisting of C$70 million in Tilray Class 2 common stock at closing and $40 million in Common Stock subject to the achievement of certain performance milestones by FOUR20.

Earlier today, Cronos Group (NASDAQ: CRON) reported its third quarter results in which the company swung to a profit from a loss year ago. Revenue rose sharply to CAD12.7 million, helped by the launch of the adult-use market in Canada and the inclusion of the Redwood business.

Rivals Aurora Cannabis (NYSE: ACB) and Canopy Growth (NYSE: CGC) will be reporting their quarterly earnings on Thursday, November 14, after the market closes.

Shares of Tilray, which plunged to a new 52-week low ($20.20) last month, lost 69% of its value so far in 2019 and plunged 81% from this time last year.

Browse through our earnings calendar and get all scheduled earnings announcements, analyst/investor conference and much more!

ADVERTISEMENT

ADVERTISEMENT